Bone marrow-derived MSC treatment was safe and well tolerated but did not show an effect on gadolinium-enhancing lesions, an MRI surrogate marker of acute inflammation, in patients with active forms of multiple sclerosis, at week 24.
[Lancet Neurology]
7992332
{7992332:CCCCCCCC}
apa
50
1
168295
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
